Waldencast Acquisition Corp. Class A WALD 深 沪
等待开盘 08-22 09:30:00 美东时间
1.645
-0.055
-3.24%
华盛通- 最 高1.68
- 今 开1.63
- 成交量 47.60万股
- 最 低 1.50
- 昨 收 1.70
- 总市值 2.02亿
- 52周最高 4.3952
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 1.50
- 委 比 49.83%
- 总股本 1.23亿
- 历史最高 12.10
- 量 比 0.35
- 振 幅 10.59%
- 历史最低 1.50
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
Waldencast plc reported strong H1 2025 performance, with Obagi Medical achieving double-digit growth in core channels and Milk Makeup delivering high-teens retail sales growth in the U.S. Obagi's acquisition of Novaestiq Corp doubles its addressable market in the U.S., while Milk Makeup expanded its digital presence through Amazon Premium Beauty. The company launched a strategic review to enhance shareholder value and postponed its H1 earnings re...
08-18 21:43
Earnings Scheduled For August 18, 2025
Companies Reporting Before The Bell • SUNation Energy (NASDAQ:SUNE) is likely t...
08-18 16:32
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
Telsey Advisory Group Maintains Outperform on Waldencast, Maintains $4 Price Target
Telsey Advisory Group analyst Dana Telsey maintains Waldencast (NASDAQ:WALD) with a Outperform and maintains $4 price target.
08-14 05:37
Waldencast Strengthens Obagi Medical With Saypha Injectable Line And Novaestiq Acquisition, Expanding Into $2B US Dermal Filler Market
Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolioNew products position Obagi Medical at the forefront of health, beauty and aesthetics convergence
07-23 18:51
Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
Waldencast plc has acquired Novaestiq Corp. and the U.S. rights to Saypha® hyaluronic acid (HA) injectable gels, expanding Obagi Medical's product offerings into the growing U.S. dermal filler market. The acquisition aims to position Obagi Medical as a leader in integrated skincare and aesthetic solutions. Saypha®, which is undergoing FDA approval, is a globally recognized, effective, and safe HA injectable with a strong clinical backing and pati...
07-23 10:45
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
06-26 20:16
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Canaccord Genuity Maintains Buy on Waldencast, Lowers Price Target to $5
Canaccord Genuity analyst Susan Anderson maintains Waldencast (NASDAQ:WALD) with a Buy and lowers the price target from $6 to $5.
05-15 20:18
